Amarin Corp Plc (AMRN)

[Whalatane]

Well Denner doesn't seem to share your blue skies outlook

The European launch is behind schedule, reimbursement in Germany (typically one of the largest markets in Europe) appears imperiled, and spending mismanagement has weakened the cash coffers.

You may not need more independent randomized clinical trial outcome data to believe the R-IT numbers and I may not need more data to believe high serum EPA levels reduce CV events ...but the Germans definitely want more data before they reimburse at a price pt AMRN can make $ on .

Better hope that France , Italy and Spain dont follow their lead .

Kiwi